Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive that the company has received regulatory approval from the UAE Department of Health to proceed with its Phase 2 clinical trial (SKNJCT-004) for the non-invasive treatment of basal cell carcinoma (BCC) of the skin. The study will enroll 36 patients across four sites in the UAE: Cleveland Clinic Abu Dhabi, Sheikh Shakhbout Medical City, Burjeel Medical City, and American Hospital of Dubai. SKNJCT-004 is a randomized, double-blind, placebo-controlled, multi-center study designed to evaluate the efficacy of two dose levels of D-MNA (Dermal Micro-Needle Array) compared to placebo. Participants will be randomly assigned in a 1:1:1 ratio to receive either a placebo (P-MNA), 100μg of D-MNA (low dose), or 200μg of D-MNA (high dose) The 200μg dose was previously tested as the maximum dose in Medicus Pharma’s Phase 1 safety and tolerability study (SKNJCT-001), completed in March 2021. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch #SkinCancer #BasalCellCarcinoma #BiotechNews #CancerResearch #UAEHealth #NonInvasiveTherapy #Doxorubicin #ClinicalTrials #HealthcareInnovation